DBV DBV Technologies SA

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information

Châtillon, France, January 13, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024:

  • 266,868 DBV Technologies shares,
  • € 106,930.51.

When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:

  • 41,159 DBV Technologies shares,
  • € 432,367.25.

Over the period from July 1, 2024, to December 31, 2024, the following transactions were executed:

  • 1682 buy transactions,
  • 1800 sales transactions.

Over this same period, the volumes traded represented:

  • 404,081 shares and € 296,390.97 on purchases,
  • 440,957 shares and € 340,906.76 on sales.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit  and engage with us on  and .

Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.

Investor Contact

Katie Matthews

DBV Technologies

Media Contact

Angela Marcucci

DBV Technologies

Attachment



EN
13/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Profess...

 PRESS RELEASE

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO Châtillon, France, le 25 février (22 :30 CEST) 2025 DBV Technologies participera au prochain congrès conjoint AAAAI/WAO DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), une société biopharmaceutique au stade clinique a annoncé aujourd'hui que la société participerait au congrès conjoint de l'American Academy of Allergy, Asthma, and Immunology et de la World Allergy Organization (AAAAI/WAO), qui se tiendra du 28 février au 3 mars 2025 à San Diego (Californie). David Fleischer, FAAAAI, FA...

 PRESS RELEASE

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO ...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares,€...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BH...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. Au titre du contrat de liquidité confié à ODDO BHF, portant sur les actions de la société DBV TECHNOLOGIES, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité...

 PRESS RELEASE

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase ...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch